NCT06230588

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study was divided into three parts: single and multiple dosing and food effect study, which were designed to evaluate the safety and tolerability of TQH3906 capsules administered in single or multiple dose escalation in healthy adult subjects.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	TQH3906 capsule	TQH3906 is a kinase inhibitor.
DRUG	TQH3906 placebo	Placebo Comparator

Timeline

• Start date: 2024-02-02
• Primary completion: 2025-04-27
• Completion: 2025-04-27
• First posted: 2024-01-30
• Last updated: 2025-07-16

Locations

1 site across 1 country: China